Background /Aims: Up to more than 50% of cryptogenetic stroke patients and patients with migraine with aura (MA) are found to have a right-to-left shunt (RLS), which is usually due to a patent foramen ovale. Moreover, both MA and stroke are cardinal features of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL). Notch3 mutations have been suggested to induce an abnormally high incidence of atrial septal defects in a family harbouring an Arg141Cys pathogenetic mutation. We sought to determine the prevalence of RLS in CADASIL patients with different Notch3 mutations, both with and without migraine as a clinical feature. Methods: Subjects with a molecular diagnosis of CADASIL were tested for the presence of an RLS by means of contrast-enhanced transcranial Doppler (TCD). The diagnosis of migraine was made according to the 2004 International Headache Classification. Results: Sixteen CADASIL patients were tested; 6 had MA. Four patients displayed an RLS on contrast-enhanced TCD examination. Three of these patients had MA. Both patients with Arg141Cys displayed a large RLS. Conclusion: We conclude that RLS is not necessarily linked to CADASIL as a comorbidity factor. Nevertheless, there could be a relation between RLS and specific Notch3 mutations, such as Arg141Cys.

Keywords:
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy, Migraine, Right-to-left shunt, Transcranial Doppler
1.
Hagen PT, Scholz DG, Edwards WD: Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984;59:17–20.
2.
Lechat P, Mas JL, Lascaut J, et al: Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988;318:1148–1152.
3.
Cabanes L, Mas JL, Cohen A, et al: Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke 1993;24:1865–1873.
4.
Handke M, Harloff A, Olschewski, Hetzel A, Geibel A: Patent foramen ovale and cryptogenetic stroke in older patients. N Engl J Med 2007;357:2262–2268.
5.
Del Sette M, Angeli S, Leandri M, et al: Migraine with aura and right-to-left shunt on transcranial Doppler: a case-control study. Cerebrovasc Dis 1998;8:327–330.
6.
Anzola GP, Magoni M, Guindani M, et al: Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. Neurology 1999;52:1622–1625.
7.
Markus HS, Martin RJ, Simpson MA, et al: Diagnostic strategies in CADASIL. Neurology2002;59:1134–1138.
8.
Singhal S, Bevan S, Barrick T, et al: The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. Brain 2004;127:2031–2038.
9.
Angeli S, Carrera P, Del Sette M, et al: Very high prevalence of right-to-left shunt on transcranial Doppler in an Italian family with cerebral autosomal dominant angiopathy with subcortical infarcts and leukoencephalopathy. Eur Neurol 2001;46:198–201.
10.
ClinicalTrials.gov: http://www.clinicaltrials.gov (accessed April 11, 2008).
11.
Dowson A, Mullen MJ, Peatfield R, et al: Migraine Intervention With STARFlex Technology (MIST) Trial. A prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation 2008;117:1397–1404.
12.
Jauss M, Zanette E: Detection of right to left shunt with ultrasound contrast agent and Transcranial Doppler sonography. Cerebrovasc Dis 2000;10:490–496.
13.
Headache Classification Subcommittee of the International Headache Society: International headache classification. Cephalalgia 2004;24(suppl 1):8–160.
14.
Vérin M, Rolland Y, Landgraf F, et al: New phenotype of the cerebral autosomal dominant arteriopathy mapped to chromosome 19: migraine as the prominent clinical feature. J Neurol Neurosurg Psychiatry 1995;59:579–585.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.